NTRK1 and sarcoma: GISTs are the only sarcoma subtype that can be treated with reimbursed targeted therapy in an advanced setting up to four lines, specifically targeting KIT/PDGFRA tyrosine kinase receptors (first line imatinib, second line sunitinib and third line regorafenib).